Indian drugmaker Dr Reddy's Laboratories is likely to launch its generic semaglutide injection in the country in March under the brand name Obeda, according to two people familiar with the matter as well as images reviewed by Reuters. The compound is the active ingredient in Danish drugmaker Novo Nordisk's blockbuster diabetes drug Ozempic and weight-loss drug Wegovy. ADVERTISEMENTHyderabad-based Dr Reddy's has applied to trademark the Obeda brand and logo, a government filing showed. Dr Reddy's plans to sell about 12 million injectable semaglutide pens in the first year and intends to price it competitively, potentially up to 60% below the branded product, Dr Reddy's Co-Chairman and Managing Director G.V. The company has regulatory approval to manufacture and sell a generic version of Ozempic and is awaiting clearance for a generic Wegovy, the company said earlier.

Source: The Telegraph February 25, 2026 09:27 UTC